TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3979482

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30045066

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.0-2.0 mg/day
Number of subjects: 231

Group type: COMPARATOR
Intervention: Cariprazine 0.1-0.3 mg/day
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 24804780

Group type: EXPERIMENTAL
Intervention: Alcohol dependence group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol dependence group with family history of alcohol dependence
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol dependence group with more frequent drinking
Number of subjects: 48

Group type: COMPARATOR
Intervention: Psychiatrically healthy adults
Number of subjects: 48
Study: 20694822

Group type: EXPERIMENTAL
Intervention: Pre- and post-radiotherapy fatigue education and support (RFES)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pre-RFES only
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Post-RFES only
Number of subjects: 110

Group type: COMPARATOR
Intervention: No RFES (standard care)
Number of subjects: 110
Study: 16149361

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CR oxycodone)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 171
Study: 12399282

Group type: EXPERIMENTAL
Intervention: Multivitamins (thiamine, riboflavin, niacin, folic acid, vitamins B‐6, B‐12, C, and E)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Multivitamins including vitamin A
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 9799882

Group type: EXPERIMENTAL
Intervention: Alpha tocopherol 50 mg per day
Number of subjects: 28934

Group type: EXPERIMENTAL
Intervention: Beta carotene 20 mg per day
Number of subjects: 28934

Group type: EXPERIMENTAL
Intervention: Both alpha tocopherol and beta carotene
Number of subjects: 28934

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28934
Study: 7893315

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Categorical Scale
Number of subjects: 4
Study: 2777011

Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Upright bicycle exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Measurement of myocardial perfusion using thallium-201 radionuclide ventriculography
Number of subjects: 50
Study: 383099

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29524793

Group type: EXPERIMENTAL
Intervention: Unconditional non‐monetary gifts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditional gift based on performance target
Number of subjects: 0
Study: 24612734

Group type: EXPERIMENTAL
Intervention: Axaven(®) once a day for 8 months as adjunctive treatment with standard treatment (compression therapy and surgical correction of superficial venous incompetence)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Basic treatment according to clinical conditions (control group)
Number of subjects: 83
Study: 25587162

Group type: EXPERIMENTAL
Intervention: Endotracheal liquid bolus (ELB) albuterol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Metered-dose inhaler (MDI) albuterol
Number of subjects: 14
Study: 23669879

Group type: EXPERIMENTAL
Intervention: CAFF 3mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CAFF 6mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CAFF 9mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 13
Study: 19830449

Group type: EXPERIMENTAL
Intervention: Stage-matched information
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Stage-mismatched information
Number of subjects: 1076

Group type: COMPARATOR
Intervention: General information
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Personalized feedback
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Standardized feedback
Number of subjects: 1076
Study: 18718737

Group type: COMPARATOR
Intervention: Standard formula (STND)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Slowly digested carbohydrate formula (SDC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 48
Study: 16384948

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 16 mg twice daily for 28 days
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) (8 mg twice a day, 16 mg per day, or 16 mg twice a day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX)
Number of subjects: 29
Study: 14598034

Group type: EXPERIMENTAL
Intervention: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to students instructed to feign conditions
Number of subjects: 266

Group type: COMPARATOR
Intervention: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to students responding honestly
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to sexually delinquent patients with antisocial personality disorders
Number of subjects: 266
Study: 10965864

Group type: EXPERIMENTAL
Intervention: Video framing the procedure as 99% safe
Number of subjects: 116

Group type: COMPARATOR
Intervention: Video framing the likelihood of complication as 1 in 100
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Both videos
Number of subjects: 116
Study: 8629845

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (FK 506) at an initial dose of 0.05 mg/kg per day, increased to 0.10 and 0.15 mg/kg per day if necessary
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (FK 506)
Number of subjects: 50
Study: 1475268

Group type: EXPERIMENTAL
Intervention: 100 mg flupirtine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 200 mg flupirtine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 6427144

Group type: EXPERIMENTAL
Intervention: Added dead space (DS) of 0.25 liter if FEV1 < 0.8, and 0.50 liter if FEV1 > 0.8
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline exercise (BL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal control subjects (9 subjects)
Number of subjects: 22
Study: 30328094

Group type: EXPERIMENTAL
Intervention: Tele-supervised (intervention)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-supervised (control)
Number of subjects: 20
Study: 29648647

Group type: EXPERIMENTAL
Intervention: Walking ≥10 min at a time
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: >4 hours/week of vigorous activity
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Moderate activity, sitting, and IPAQ categories
Number of subjects: 1214
Study: 27277940

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 17
Study: 24659064

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study: 22465404

Group type: EXPERIMENTAL
Intervention: Modified Sun style tai chi exercise
Number of subjects: 503

Group type: COMPARATOR
Intervention: Seated flexibility exercise
Number of subjects: 503
Study: 20538704

Group type: COMPARATOR
Intervention: Disease-modifying treatments (DMTs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Symptomatic treatments (STs)
Number of subjects: 100
Study: 18923170

Group type: EXPERIMENTAL
Intervention: Monovalent type 1 oral poliovirus vaccine
Number of subjects: 530

Group type: COMPARATOR
Intervention: Trivalent oral poliovirus vaccine
Number of subjects: 530
Study: 15892276

Group type: EXPERIMENTAL
Intervention: Erigeron injection (EI) 40 ml/d for 15 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 68
Study: 11936731

Group type: EXPERIMENTAL
Intervention: Vitamin A supplements for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no vitamin A supplements)
Number of subjects: 20
Study: 9894936

Group type: EXPERIMENTAL
Intervention: Heat shock‐inactivated herpes simplex virus type 1 (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Comparison between vaccine and control groups
Number of subjects: 20
Study: 7737395

Group type: EXPERIMENTAL
Intervention: Intrinsic kinesthetic coordinate system (shoulder angles relative to trunk)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Extrinsic kinesthetic coordinate system (arm angles relative to earth)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Extrinsic kinesthetic coordinate system (yaw angles)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Elevation angles
Number of subjects: 7
Study: 2076677

Group type: EXPERIMENTAL
Intervention: 300 mg chloroquine base weekly for six months
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Post-intervention phase (after chloroquine withdrawal)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 3 months after initiation of chloroquine prophylaxis
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6 months of chemoprophylaxis
Number of subjects: 17
Study: 7191229

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 0.0045 mg/kg IV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 0.008 mg/kg IV
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atropine, 0.009 mg/kg IV
Number of subjects: 60
Study: 31118090

Group type: EXPERIMENTAL
Intervention: MiQuit programme of tailored, interactive text message, and self‐help cessation support for 12 weeks
Number of subjects: 692

Group type: COMPARATOR
Intervention: Standard NHS smoking cessation support and a leaflet on stopping smoking during pregnancy
Number of subjects: 692
Study: 26241157

Group type: EXPERIMENTAL
Intervention: Multitarget deep brain stimulation (DBS) involving GPi and Vim/Vop
Number of subjects: 1

Group type: COMPARATOR
Intervention: Single-target deep brain stimulation (DBS)
Number of subjects: 1
Study: 23898610

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional Radiotherapy
Number of subjects: 69
Study: 21849626

Group type: EXPERIMENTAL
Intervention: PF-02413873
Number of subjects: 0

Group type: COMPARATOR
Intervention: RU-486 (mifepristone)
Number of subjects: 0
Study: 19142668

Group type: EXPERIMENTAL
Intervention: HA+FU infusion group
Number of subjects: 16
Study: 16905785

Group type: EXPERIMENTAL
Intervention: Breastfeeding plus infant zidovudine for 6 months
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Formula feeding plus infant zidovudine for 1 month
Number of subjects: 1179
Study: 15262838

Group type: EXPERIMENTAL
Intervention: Eptifibatide with tenecteplase
Number of subjects: 70
Study: 11320642

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 16
Study: 9734727

Group type: EXPERIMENTAL
Intervention: Aspartame (high dose: 45 mg x kg body wt(-1) x d(-1))
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aspartame (low dose: 15 mg x kg body wt(-1) x d(-1))
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 48
Study: 7999480

Group type: EXPERIMENTAL
Intervention: Topical analgesia
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dorsal nerve block (midline approach)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dorsal nerve block (lateral approach)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 3402466

Group type: EXPERIMENTAL
Intervention: Dopexamine hydrochloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 12
Study: 31399381

Group type: EXPERIMENTAL
Intervention: Personalised mechanical ventilation (based on lung morphology); tidal volume of 8 mL/kg for focal ARDS, 6 mL/kg for non-focal ARDS, low PEEP, recruitment manoeuvres, and prone position.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group received standard care; tidal volume of 6 mL/kg, low PEEP, and encouraged early prone position.
Number of subjects: 420
Study: 30095773

Group type: EXPERIMENTAL
Intervention: Individualized oxycodone prescription (predicted based on each patient's inpatient opioid use)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard oxycodone prescription (30 tablets of 5 mg oxycodone)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Individualized oxycodone prescription
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard oxycodone prescription
Number of subjects: 172
Study: 27159341

Group type: COMPARATOR
Intervention: Varenicline 2mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Varenicline 1mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plasma varenicline levels ≥3ng/mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Plasma varenicline levels ≥5ng/mL
Number of subjects: 60
Study: 25393358

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) guided access
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fluoroscopic guided access
Number of subjects: 64
Study: 22178347

Group type: EXPERIMENTAL
Intervention: Laparoscopic extraperitoneal adenomectomy (LEA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 46
Study: 20194013

Group type: COMPARATOR
Intervention: Oxytocin 5-unit bolus and placebo infusion
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oxytocin 5-unit bolus and oxytocin 30-unit infusion
Number of subjects: 74
Study: 17638549

Group type: EXPERIMENTAL
Intervention: Oral diclofenac sodium (50 mg for body weight <70 kg; 100 mg for body weight >70 kg) 60 minutes prior to SWL
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Topical EMLA (5 g) 60 minutes prior to SWL
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of oral diclofenac sodium and topical EMLA (5 g) 60 minutes prior to SWL
Number of subjects: 240
Study: 16079682

Group type: EXPERIMENTAL
Intervention: Wrist with arteriovenous fistula
Number of subjects: 279

Group type: COMPARATOR
Intervention: Contralateral wrist (control)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Duration of fistula
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Site of fistula (snuffbox, radiocephalic)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic studies
Number of subjects: 279
Study: 11061518

Group type: COMPARATOR
Intervention: Standard recombinant human GH therapy (0.3 mg/kg x week)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High dose recombinant human GH therapy (0.7 mg/kg x week)
Number of subjects: 97
Study: 9279533

Group type: EXPERIMENTAL
Intervention: Glibenclamide 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8336373

Group type: EXPERIMENTAL
Intervention: Drug treatment (chlorthalidone, acebutolol, doxazosin mesylate, amlodipine maleate, enalapril maleate)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Drug treatment (all drug groups combined)
Number of subjects: 731
Study: 3459351

Group type: EXPERIMENTAL
Intervention: Standard gemfibrozil dosage of two 300-mg capsules 2 times a day (total 1200 mg daily)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: 600-mg tablet of gemfibrozil 2 times a day (total 1200 mg daily)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Two 450-mg tablets of gemfibrozil once a day in the evening
Number of subjects: 321
Study: 2968669

Group type: EXPERIMENTAL
Intervention: Colchicine capsule (burst dose regimen)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 27
Study: 31064666

Group type: EXPERIMENTAL
Intervention: Liquid oral nutritional supplement (ONS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Semi solid inbetween meal snack (snack)
Number of subjects: 17
Study: 29474130

Group type: EXPERIMENTAL
Intervention: Viewing a prime-time television clip depicting public breastfeeding
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Entertainment media messages
Number of subjects: 375
Study: 29101841

Group type: EXPERIMENTAL
Intervention: One Session Treatment (OST)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Educational Support Therapy (C)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 165
Study: 25933976

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg containing 50mg zinc element) for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 43
Study: 23328851

Group type: EXPERIMENTAL
Intervention: Forefoot off‐loading postoperative shoe (FOPS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Forefoot off‐loading postoperative shoe (FOPS) with contralateral shoe raise
Number of subjects: 14
Study: 21284697

Group type: EXPERIMENTAL
Intervention: Nicotine Patch (Nicotinell Patch 10cm(2), 17.5mg nicotine, average delivery rate 7mg/24h)
Number of subjects: 90
Study: 19307503

Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m² (arm A)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² plus carboplatin AUC 5 (arm B)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Patients with MTHFR C677T homozygous mutation
Number of subjects: 240
Study: 17073957

Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS) suture
Number of subjects: 366

Group type: COMPARATOR
Intervention: Stainless steel (SS) sternal approximation
Number of subjects: 366
Study: 15085019

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Control formula with medium-chain triglyceride and dextrinomaltose (group A: 33:66 ratio)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Control formula with medium-chain triglyceride and dextrinomaltose (group B: 66:33 ratio)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Control formula with medium-chain triglyceride and dextrinomaltose (group C: 85:15 ratio)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control formula (group D)
Number of subjects: 4
Study: 11134438

Group type: COMPARATOR
Intervention: Oral iron group (9 mg/kg/day of iron polymaltose complex)
Number of subjects: 29

Group type: COMPARATOR
Intervention: EPO + oral iron group (300 U of recombinant human EPO kg/day and daily oral IPC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous iron + EPO group (2 mg/kg/day of intravenous iron sucrose, r‐HuEPO, and oral iron)
Number of subjects: 29
Study: 9205169

Group type: EXPERIMENTAL
Intervention: Reconstructed ascending aorta
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonreconstructed aorta
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Descending aorta (both reconstructed and nonreconstructed)
Number of subjects: 22
Study: 8381146

Group type: EXPERIMENTAL
Intervention: Intralesional vinblastine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bicarbonate buffered lidocaine (BBL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vinblastine mixed with BBL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vinblastine 5 minutes after BBL injection
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control lesions (BBL, saline, or no treatment)
Number of subjects: 11
Study: 3302110

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 25
Study: 31675595

Group type: EXPERIMENTAL
Intervention: Distal taping (muscle application over peroneus longus)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Proximal-distal taping (muscle application over gluteus medius and peroneus longus)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 27909231

Group type: EXPERIMENTAL
Intervention: SIT and nitrate-rich beetroot juice (13 mmol/day) (SIT+BR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: SIT and nitrate-depleted beetroot juice as a placebo (SIT+PL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: No training and nitrate-rich beetroot juice (NT+BR)
Number of subjects: 36
Study: 25792254

Group type: EXPERIMENTAL
Intervention: Conventional transbronchial needle aspiration (TBNA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided TBNA (EBUS‐TBNA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle aspiration (EUS‐FNA)
Number of subjects: 100
Study: 23718639

Group type: EXPERIMENTAL
Intervention: Synthetic cathinones (bath salts)
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Hispanics and Native Americans
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Student athletes
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: Synthetic cathinones
Number of subjects: 2349
Study: 21295507

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 39
Study: 19093004

Group type: EXPERIMENTAL
Intervention: PfAMA1 with Alhydrogel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PfAMA1 with Montanide ISA720
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PfAMA1 with AS02
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All formulations (PfAMA1 with Alhydrogel, Montanide ISA720, AS02)
Number of subjects: 60
Study: 16966690

Group type: EXPERIMENTAL
Intervention: Belagenpumatucel-L (1.25, 2.5, or 5.0 x 10(7) cells/injection) administered monthly or every other month for a maximum of 16 injections
Number of subjects: 75
Study: 14582545

Group type: EXPERIMENTAL
Intervention: Cannulated screws combined with calcium‐phosphate cement for augmentation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cannulated screws alone (controls)
Number of subjects: 40
Study: 10699943

Group type: EXPERIMENTAL
Intervention: T+GLA (Gamma linolenic acid with tamoxifen 20 mg od)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg od alone
Number of subjects: 38